Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Recently, several conditioning regimens did not include total body irradiation (TBI) anymore,
especially in the case of young children due to cognitive sequelae and late effects on growth
and height. Thus, such effective chemotherapy conditioning regimens were developed to avoid
these complications. Busulfan is one of the major drugs used in these treatments, but, is
also administered in high dose chemotherapy followed by autograft. In both situations, long
term pulmonary side effects were diagnosed in a few cases. Even if the occurrence is not very
frequent, the clinical management is a real challenge regarding the reduced quality of life
and life expectancy of these patients. Up to now, no correlation was done between respiratory
sequelae and busulfan pharmacokinetics. Hence, in the investigators' pediatric
onco-hematological unit, a prospective study will begin and last three years to assess the
respiratory side effects due to busulfan and their potential links with individual drug
pharmacokinetic measures. These results will be compared to patients treated with TBI during
the same period of time.